Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT00733629

Study of Endothelial Cells in Patients With Hereditary Haemorrhagic Telangiectasia

In Vitro Studies pf Endothelial Cells Derived From HHT Patients

Status
Withdrawn
Phase
Study type
Observational
Enrollment
0 (actual)
Sponsor
Imperial College London · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

Hereditary Haemorrhagic Telangiectasia (HHT, also known as Osler-Weber-Rendu Syndrome) is an disease that leads to the development of dilated and fragile blood vessels. We propose to culture endothelial cells from patients with HHT, to culture cells that express the proteins mutated in HHT, namely endoglin and ALK-1. We will study the properties of these cells which will involve their growth in different conditions and anticipate that DNA, mRNA and proteins will be extracted from these cells for study of cell responses and association with expression levels of endoglin and ALK-1. We hypothesize that these cells which express "half-normal" endoglin or ALK-1 will show altered protein synthetic differences when compared to normal white blood cells. We anticipate that that these findings may help to explain aspects of the HHT disease phenotype.

Conditions

Timeline

Start date
2002-08-01
Primary completion
2006-03-01
Completion
2006-03-01
First posted
2008-08-13
Last updated
2019-10-09

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT00733629. Inclusion in this directory is not an endorsement.